Evidence map›Paper›PMID 30585483›Full record

Trial reportACS infectious diseases2019

Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy.

Bryna L Fitzgerald, M Nurul Islam, Barbara Graham, Sebabrata Mahapatra, Kristofor Webb, W Henry Boom, Stephanus T Malherbe, Moses L Joloba, John L Johnson, Jill Winter and 2 more

Erratum issuedAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ACS infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Biomarker discovery for tuberculosis using metabolomics.Frontiers in molecular biosciences · 2023
    Review
  8. Review
  9. Perspectives for systems biology in the management of tuberculosis.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Bryna L FitzgeraldMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology , Colorado State University , 200 West Lake Street, 0922 Campus Delivery , Fort Collins , Colorado 80523 , United States.
M Nurul IslamMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology , Colorado State University , 200 West Lake Street, 0922 Campus Delivery , Fort Collins , Colorado 80523 , United States.
Barbara GrahamMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology , Colorado State University , 200 West Lake Street, 0922 Campus Delivery , Fort Collins , Colorado 80523 , United States.
Sebabrata MahapatraMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology , Colorado State University , 200 West Lake Street, 0922 Campus Delivery , Fort Collins , Colorado 80523 , United States.
Kristofor WebbMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology , Colorado State University , 200 West Lake Street, 0922 Campus Delivery , Fort Collins , Colorado 80523 , United States.
W Henry BoomDepartment of Medicine, Tuberculosis Research Unit (TBRU) , Case Western Reserve University , 10900 Euclid Avenue , Cleveland , Ohio 44106 , United States.
Stephanus T MalherbeDST/NRF Centre of Excellence for Biomedical Tuberculosis Research and MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences , Stellenbosch University , P.O. Box 241, Francie van Zijl Drive , Cape Town 8000 , South Africa.
Moses L JolobaSchool for Biomedical Sciences , Makerere University , P.O. Box 7062, Kampala , Uganda.
John L JohnsonDepartment of Medicine, Tuberculosis Research Unit (TBRU) , Case Western Reserve University , 10900 Euclid Avenue , Cleveland , Ohio 44106 , United States.
Jill WinterCatalysis Foundation for Health , 2100 Addison Street , Berkeley , California 94704 , United States.
Gerhard WalzlDST/NRF Centre of Excellence for Biomedical Tuberculosis Research and MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences , Stellenbosch University , P.O. Box 241, Francie van Zijl Drive , Cape Town 8000 , South Africa.
John T BelisleMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology , Colorado State University , 200 West Lake Street, 0922 Campus Delivery , Fort Collins , Colorado 80523 , United States.ORCID 0000-0002-2539-2798

Funding

Biology and Biosignatures of Anti-Tuberculosis Treatment ResponseU01AI115619 · NIAID · COLORADO STATE UNIVERSITY · PI BELISLE, JOHN T · 2015 to 2019
$3.1M
NCI NIH HHS HHSN261200700022CNIAID NIH HHS N01 AI070022NIAID NIH HHS U01 AI115619
6 · The paper itself

Abstract

The evaluation of new tuberculosis (TB) therapies is limited by the paucity of biomarkers to monitor treatment response. Previous work detected an uncharacterized urine metabolite with a molecular mass of 874.3547 Da that showed promise as a biomarker for successful TB treatment. Using mass spectrometry combined with enzymatic digestions, the metabolite was structurally characterized as a seryl-leucine core 1 O-glycosylated peptide (SLC1G) of human origin. Examination of SLC1G in urine revealed a significant abundance increase in individuals with active TB versus their household contacts and healthy controls. Moreover, differential decreases in SLC1G levels were observed by week one in TB patients during successful treatment versus those that failed treatment. The SLC1G levels were also associated with clinical parameters used to measure bacterial burden (GeneXpert) and inflammation (positron emission tomography-computed tomography (PET-CT)). These results demonstrate the importance of metabolite identification and provide strong evidence for applying SLC1G as a biomarker of TB treatment response.

Indexed as

AdultAntitubercular AgentsBiomarkersDrug MonitoringFemaleGlycopeptidesHumansLeucineMaleMass SpectrometryMiddle AgedTuberculosisUrineYoung AdultAntitubercular AgentsBiomarkersGlycopeptidesLeucinecore 1 oligosaccharideglycopeptidemass spectrometryPET-CTprognostic biomarkertreatment responsetuberculosisurine metabolite

Identifiers

PMID30585483
PMCPMC6412501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.